ALEMBIC-TELMISARTAN/HCTZ TABLET
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
30-03-2022
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
HYDROCHLOROTHIAZIDE; TELMISARTAN
Inapatikana kutoka:
ALEMBIC PHARMACEUTICALS LIMITED
ATC kanuni:
C09DA07
INN (Jina la Kimataifa):
TELMISARTAN AND DIURETICS
Kipimo:
12.5MG; 80MG
Dawa fomu:
TABLET
Tungo:
HYDROCHLOROTHIAZIDE 12.5MG; TELMISARTAN 80MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
(10X10)/30/1000
Dawa ya aina:
Prescription
Eneo la matibabu:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0244783001; AHFS:
Idhini hali ya:
APPROVED
Idhini ya tarehe:
2018-08-09
Tabia za bidhaa
_Alembic-Telmisartan/HCTZ Product Monograph _
_Page 1 of 57 _
_ _
PRODUCT MONOGRAPH
PR
ALEMBIC-TELMISARTAN/HCTZ
Telmisartan and Hydrochlorothiazide Tablets, USP
80 mg/12.5 mg
80 mg/25 mg
(telmisartan/hydrochlorothiazide)
Angiotensin II AT
1
Receptor Blocker/Diuretic
MANUFACTURED BY:
Alembic Pharmaceuticals Limited
Alembic Road,
Vadodara 390003,
Gujarat, India
IMPORTED AND DISTRIBUTED BY:
Alembic Pharmaceuticals Canada Ltd.
225 Gibraltar Road, Unit 5
Vaughan, Ontario
L4H 4P9, Canada
CONTROL NUMBER:
256615
DATE OF PREPARATION:
March 30, 2022
_ _
_Alembic-Telmisartan/HCTZ Product Monograph _
_Page 2 of 57_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................12
DRUG INTERACTIONS
..................................................................................................22
DOSAGE AND ADMINISTRATION
..............................................................................28
OVERDOSAGE
................................................................................................................29
ACTION AND CLINICAL PHARMACOLOGY
............................................................30
STORAGE AND STABILITY
..........................................................................................36
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................36
PART II: SCIENTIFIC INFORMATION
...............................................................................
Soma hati kamili
